Eckert & Ziegler Strahlen- und Medizintechnik AG / Miscellaneous
01.04.2010 14:11
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, 01.04.2010 - In the course of a consolidation of minority
shareholding and the simplification of the corporate organisation Eckert &
Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) takes over the
remaining 30% shares of senior shareholders of EURO-PET Berlin Zyklotron
GmbH Berlin (EURO-PET) and several shareholder loans. The pharmaceutical
company on the premises of the scientific campus Adlershof which
specialises in the production of short-lived isotopes for nuclear imaging
thus becomes a 100% affiliate of Eckert & Ziegler AG. EURO-PET remains
affiliated to its senior shareholders by co-operations in sales and the
licensing of new drugs which were agreed upon in the scope of the
assignment of the interests.
With the complete takeover of EURO-PET Eckert & Ziegler intends to continue
to boost its position on the growing market for radioactive pharmaceutical
products. The Holding already has a number of radiopharmaceutical
production locations in Germany and markets the approved product
Yttriga(R), a preliminary stage of many radiotherapy treatments, as well as
fluorine-18-based radiodiagnostic compounds for nuclear medical imaging
(PET). In addition, Eckert & Ziegler supplies nuclear-imaging facilities
around the world with synthesis technology and gallium-68 radionuclide
generators.
PET is the abbreviation for positron emission tomography and describes a
technique which uses a special camera to make the very smallest quantities
of a slightly radioactive contrast agent visible and it is used for
diagnosis. This powerful and ground-breaking technology is becoming more
and more important in the diagnosis of cancers and neurologic diseases like
Alzheimer's because it spares the patient a burdensome marathon of
diagnosis and operations carried out only on the basis of a tentative
diagnosis.
The Eckert & Ziegler group with some 520 employees belongs to the largest
suppliers of isotope technology components for radiation therapy and
nuclear medicine world-wide. In the previous fiscal year 2009 the company
made a turnover of more than EUR 100 million and earnings of some EUR 13.3
million.
Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations,
Robert-Rössle-Str. 10, 13125 Berlin
Phone: +49 (0) 30 / 94 10 84-138, Fax -112,
e-mail: karolin.riehle@ezag.de, www.ezag.com
01.04.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg
End of News DGAP News-Service
---------------------------------------------------------------------------
